scispace - formally typeset
X

Xizi Deng

Researcher at Guangzhou Medical University

Publications -  26
Citations -  583

Xizi Deng is an academic researcher from Guangzhou Medical University. The author has contributed to research in topics: Medicine & Hepatitis B virus. The author has an hindex of 4, co-authored 17 publications receiving 320 citations.

Papers
More filters
Journal ArticleDOI

Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China.

TL;DR: In this article, the authors reported the epidemiological, viral, and clinical characteristics of hospitalized patients infected with the Delta variant of concern (VOC), also known as lineage B. The whole chain of the Delta VOC transmission was described and compared with a cohort of wild-type infection in 2020 admitted to the Guangzhou Eighth People's Hospital.
Journal ArticleDOI

Prognostic roles of KL-6 in disease severity and lung injury in COVID-19 patients: A longitudinal retrospective analysis.

TL;DR: In this paper, the authors investigated the dynamic changes of Krebs von den Lungen-6 (KL-6) among patients with coronavirus disease 2019 (COVID-19) and the role of KL-6 as a noninvasive biomarker for predicting long-term lung injury.
Journal ArticleDOI

Transmitted drug resistance and transmission clusters among HIV-1 treatment-naïve patients in Guangdong, China: a cross-sectional study.

TL;DR: Wang et al. as discussed by the authors investigated the prevalence of transmitted drug resistance (TDR) and the transmission clusters of HIV-1 infected persons before ART in Guangdong, China and found that the overall prevalence of TDR was 2.20% (52/2368).
Journal ArticleDOI

Absence of Integrase Inhibitor-Associated Resistance Among Antiretroviral Therapy-Naïve HIV-1-Infected Adults in Guangdong Province, China, in 2018.

TL;DR: Drug resistance mutation testing for the detection of INSTI drug resistance mutations in HIV treatment-naïve patients should be considered due to the circulation of polymorphisms contributing to INSTI resistance and the expected increasing use of this class of drugs.